BioSpace News Archive

Gelesis, the maker of Plenity, announced preliminary results from its broad awareness media campaign that debuted January 31, 2022.

TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the Canaccord Geunity Musculoskeletal Conference on March 22, 2022 in Chicago, IL.

EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Company’s President & CEO, David P. Luci, has been invited to present at the 2022 Virtual Growth Conference.

Novamind Inc. is pleased to announce it has been selected by Mind Medicine, Inc. to host a phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder (GAD) in adults.

Oramed Pharmaceuticals Inc. today announced it has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH).

The DeGregorio Family Foundation, with the support of the Price Family Foundation and the Esophageal Cancer Awareness Association, has awarded $250,000 to Paraskevi Giannakakou, PhD, Professor of Pharmacology in Medicine at Weill Cornell Medicine.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the fourth quarter and full year 2021 and provided an update on recent corporate activities.

Relmada Therapeutics, Inc. today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021 after the market close on Wednesday, March 23, 2022 .

Thermo Fisher Scientific, the world leader in serving science, has introduced a new large-volume electroporation system that allows cell therapy developers to more easily move from clinical development to commercial manufacturing.